RxDoctor Payments DataLook up a doctor →

Russell Swan, MD

Ophthalmology · Bozeman, MTNPI 1225304918

Payments from drug & device makers

$1,612,228in general payments, 2019–2025

Across 458 payments — averaging $3520.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$970K
  • Ocular Therapeutix, Inc.$228K
  • Oyster Point Pharma, Inc.$198K
  • Beaver-visitec International, Inc.$116K
  • Alcon Research LLC$71K
  • Sight Sciences, Inc.$25K
  • plus $5K from 14 others
$173,179in research payments, 2019–2025

Across 1 payment — averaging $173,179 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Beaver-visitec International, Inc.$173K

What the payments were for

  • Consulting fees$126,74488%
  • Speaking & faculty fees$5260%
  • Travel & lodging$1,8301%
  • Food & beverage$5,5984%
  • Education$1300%
  • Gifts$750%
  • Charitable contribution$9001%
  • Other$7,4755%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,612,228 in reported general payments places this provider in the 95th percentile of 52 ophthalmology providers in Montana.

See all ophthalmology providers in Montana

Medicare billing

Part B allowed, 2024
$748,880
Medicare patients
938
Services billed
2,835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IlevroNepafenac16$11,119
Prednisolone Acetate38$2,277
MoxifloxacinMoxifloxacin Hcl37$1,320
Ketorolac Tromethamine16$474

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Bozeman

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →